I Boege1, N Corpus2, R Schepker3, R Kilian4, J M Fegert3. 1. ZfP Suedwuerttemberg, Child and Adolescent Psychiatry, Weingartshoferstrasse 2, 88214 Ravensburg, Germany; University of Ulm, Department of Child and Adolescent Psychiatry, Ulm, Germany. Electronic address: Isabel.Boege@zfp-zentrum.de. 2. ZfP Suedwuerttemberg, Child and Adolescent Psychiatry, Weingartshoferstrasse 2, 88214 Ravensburg, Germany. 3. University of Ulm, Department of Child and Adolescent Psychiatry, Ulm, Germany. 4. University of Ulm, Psychiatry II, BKH Günzburg, Günzburg, Germany.
Abstract
BACKGROUND:Admission rate to child and adolescent mental health inpatient units in Germany is high (54,467 admissions in 2013), resources for providing necessary beds are scarce. Alternative pathways to care are needed. Objective of this study was to assess the cost-effectiveness of inpatient treatment versus Hot-BITs-treatment (Hometreatment brings inpatient-treatment outside), a new supported discharge service offering an early discharge followed by 12 weeks of intensive support. METHODS: Of 164 consecutively recruited children and adolescents, living within families and being in need of inpatient mental health care, 100 patients consented to participate and were randomised via a computer-list into intervention (n=54) and control groups (n=46). Follow-up data were available for 76 patients. Primary outcome was cost-effectiveness. Effectiveness was gathered by therapist-ratings on the Children's Global Assessment Scale (CGAS) at baseline (T1), treatment completion (T2) and an 8-month-follow-up (T3). Cost of service use (health care costs and non-health care costs) was calculated on an intention-to-treat basis at T2 and T3. RESULTS: Significant treatment effects were observed for both groups between T1/T2 and T1/T3 (P<0.001). The Hot-BITs treatment, however, was associated with significantly lower costs at T2 (difference: -6900.47€, P=0.013) and T3 (difference: -8584.10€, P=0.007). Bootstrap cost-effectiveness ratio indicated that Hot-BITs was less costly and tended to be more effective at T2 and T3. CONCLUSIONS: Hot-BITs may be a feasible cost-effective alternative to long inpatient stays in child and adolescent psychiatry. Further rigorous evaluations of the model are required. ( REGISTRATION NUMBER: ISRCTN02672532, part 1, Current Controlled Trials Ltd, URL: http://www.controlled-trials.com).
RCT Entities:
BACKGROUND: Admission rate to child and adolescent mental health inpatient units in Germany is high (54,467 admissions in 2013), resources for providing necessary beds are scarce. Alternative pathways to care are needed. Objective of this study was to assess the cost-effectiveness of inpatient treatment versus Hot-BITs-treatment (Hometreatment brings inpatient-treatment outside), a new supported discharge service offering an early discharge followed by 12 weeks of intensive support. METHODS: Of 164 consecutively recruited children and adolescents, living within families and being in need of inpatient mental health care, 100 patients consented to participate and were randomised via a computer-list into intervention (n=54) and control groups (n=46). Follow-up data were available for 76 patients. Primary outcome was cost-effectiveness. Effectiveness was gathered by therapist-ratings on the Children's Global Assessment Scale (CGAS) at baseline (T1), treatment completion (T2) and an 8-month-follow-up (T3). Cost of service use (health care costs and non-health care costs) was calculated on an intention-to-treat basis at T2 and T3. RESULTS: Significant treatment effects were observed for both groups between T1/T2 and T1/T3 (P<0.001). The Hot-BITs treatment, however, was associated with significantly lower costs at T2 (difference: -6900.47€, P=0.013) and T3 (difference: -8584.10€, P=0.007). Bootstrap cost-effectiveness ratio indicated that Hot-BITs was less costly and tended to be more effective at T2 and T3. CONCLUSIONS: Hot-BITs may be a feasible cost-effective alternative to long inpatient stays in child and adolescent psychiatry. Further rigorous evaluations of the model are required. ( REGISTRATION NUMBER: ISRCTN02672532, part 1, Current Controlled Trials Ltd, URL: http://www.controlled-trials.com).
Authors: Dennis Ougrin; Richard Corrigall; Jason Poole; Toby Zundel; Mandy Sarhane; Victoria Slater; Daniel Stahl; Paula Reavey; Sarah Byford; Margaret Heslin; John Ivens; Maarten Crommelin; Zahra Abdulla; Daniel Hayes; Kerry Middleton; Benita Nnadi; Eric Taylor Journal: Lancet Psychiatry Date: 2018-05-03 Impact factor: 27.083
Authors: J Mattheß; M Eckert; K Richter; G Koch; T Reinhold; P Vienhues; A Berghöfer; S Roll; T Keil; F Schlensog-Schuster; K von Klitzing; C Ludwig-Körner; L Kuchinke Journal: Trials Date: 2020-06-05 Impact factor: 2.279
Authors: Jet B Muskens; Pierre C M Herpers; Caroline Hilderink; Patricia A M van Deurzen; Jan K Buitelaar; Wouter G Staal Journal: BMC Psychiatry Date: 2019-12-19 Impact factor: 3.630
Authors: Carlos Llanes-Álvarez; Jesús M Andrés-de Llano; Ana I Álvarez-Navares; M Teresa Pastor-Hidalgo; Carlos Roncero; Manuel A Franco-Martín Journal: J Clin Med Date: 2019-12-02 Impact factor: 4.241
Authors: Hugo López-Pelayo; Henri-Jean Aubin; Colin Drummond; Geert Dom; Francisco Pascual; Jürgen Rehm; Richard Saitz; Emanuele Scafato; Antoni Gual Journal: BMC Med Date: 2020-07-31 Impact factor: 8.775